Uncategorized
Shire applies for marketing authorization in Europe for lifitegrast
A marketing authorization application in the U.K. for lifitegrast for the treatment of dry eye disease has been validated, according to a Shire press release.If approved, lifitegrast would be the first LFA-1 antagonist to address signs and symptoms of dry eye disease in adults in Europe, the release said.